Illumina, Inc. (ILMN) fell 5.71% today after opening with an upside gap, as investors responded to recent quarterly revenue gains and clinical adoption news. The sharp pullback contradicts the ...
Illumina, Inc. (ILMN) surged 5.32% today as technical momentum and bullish buying pressure powered shares higher. This advance is supported by the stock’s strong position above short-, medium-, ...
Regulatory scrutiny is intensifying for multi-cancer early detection tools as Grail moves closer to a U.S. approval decision for its blood-based screening test. An FDA advisory panel backs the ...
Illumina is continuing to climb even as broader market sentiment remains focused on interest rates, AI and uneven biotech performance. The advance follows a long period of regulatory setbacks, ...
Illumina, Inc. (ILMN) surged 3.26% today as renewed optimism followed its re-inclusion in the S&P 500 and confirmation of sustained earnings growth. The move is supported by strong upward ...
Illumina, Inc. (ILMN) surged 3.19% after new institutional buying and an upbeat Q2 revenue report fueled investor demand. The advance is reinforced by the stock trading firmly above all key moving ...
Illumina, Inc. (ILMN) surged 7.16% after issuing $300 million in new notes, boosting its liquidity as investors react positively to a fresh funding round. The bullish structure is reinforced by ...
Illumina, Inc. (ILMN) rose 3.68% after reporting stronger-than-expected quarterly revenue and raising full-year earnings guidance, driving renewed buying interest. The move is supported by the ...
Illumina (ILMN) stock is trading at $176.56 after a daily drop of 2.51%. The price finished near session lows, now below its short-term moving averages but above ...
Illumina, Inc. (ILMN) dropped 2.04% after Roche launched a new next-generation gene sequencing machine aimed at competing with Illumina's market position. The move faces limits, with bullish ...